Biotech firm 'will not charge'NHS for breast cancer tests

By Lynn Eaton2000-09-07T00:00:00

Scottish biotechnology firm Rosgen has announced that it does not plan to charge the NHS for carrying out tests for mutations in two genes linked to breast cancer.

You need to be a subscriber to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All HSJ news by sector, topic & region
Breaking News announcements
App for mobile and offline reading
Comment and Daily Insights newsletters
Regional roundup newsletters
10 expert briefings every fortnight (Premium only)
Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)

to HSJ

Already a subscriber? Sign into your account here